Vallon Pharmaceuticals Inc. has entered into a definitive agreement to merge with GRI Bio, a California biotech company that is developing what are known as Natural Killer T (NKT) cell regulators to treat inflammatory, fibrotic and autoimmune disorders.
Vallon stock opened Wednesday at 76 cents per share, up 204% from Tuesday's closing price of 25 cents per share.
Founded in 2018, Vallon (NASDAQ: VLON) has spent the past eight months evaluating “strategic alternatives" after the company's lead…
